Researchers at Cornell University and Dana-Farber Cancer Institute found a signal in blood drawn before treatment that was linked to how long lymphoma patients went without their cancer getting worse after CAR T-cell therapy.
Among 91 patients treated at Dana-Farber, those who scored high on a measure of gene activity in their blood plasma had an 80% lower risk of cancer progression than those who scored low, the Cornell Chronicle reported. The study appeared Nov. 18 in Cell Reports Medicine. The researchers say larger studies are needed to validate the finding.
What the blood samples showed
The study focused on large B-cell lymphoma, an aggressive blood cancer. The treatment, called anti-CD19 CAR T-cell therapy, uses a patient’s own immune cells, modified to target cancer cells. Nearly half of patients receiving the therapy either fail to respond or relapse within a year, according to Cornell.
The team, led by Cornell biomedical engineering professor Iwijn De Vlaminck, analyzed pretreatment plasma samples from three groups of patients who received the same CAR T-cell product. The median age was 65. The researchers examined cell-free RNA, fragments of genetic material that cells release into the bloodstream.
Earlier biopsy research found that patients tended to fare better when the mix of cells around their tumors resembled the environment inside a lymph node. In the new study, that pattern showed up in plasma RNA. Patients whose cancer responded to treatment had higher scores than those whose cancer did not respond. Within each of the three groups, patients with above-median scores also survived longer.
The team examined immune cells from matched blood samples and did not find the same signal there. That suggests the RNA in plasma may reflect activity in the tissue around a tumor, offering researchers a way to study that environment through a blood draw.
Researchers also checked whether the score tracked with lactate dehydrogenase, a marker used to estimate how much cancer a patient has. They found no significant correlation before patients received chemotherapy to prepare for CAR T-cell therapy. In the team’s statistical models, the RNA score predicted response better than the clinical factors it was compared with.
What researchers still need to test
Glory Agun, a Cornell doctoral student and one of the study’s first authors, said the next step is to see whether the finding holds in larger groups at other institutions and among patients receiving CAR T-cell therapy in different settings. The study did not establish whether using the score to guide care would improve patient outcomes.
If further studies confirm the finding, the researchers say a blood test could help doctors identify patients with a tumor environment associated with poorer outcomes. The team proposed studying whether measures such as targeted radiation or drugs that act on certain immune cells could change that environment, and whether a second blood draw could detect a change before patients receive their CAR T cells.
Make FL1 part of your day.
Local reporting. Useful updates. More ways to stay close to your community.
Go ad-free
Support independent local reporting and enjoy FL1 without display ads.
$4.99 / month
Become a member →Cancel anytime. Third-party media players may contain ads.Get the daily briefing
Start your morning with the headlines that matter across the Finger Lakes.
Find more FL1 on Google
Choose FingerLakes1.com as a preferred source to see more of our reporting in your Google news results.



